尼古丁贴片用于重症COVID-19机械通气患者:一项随机、双盲、安慰剂对照、多中心试验
这项在法国18个ICU开展的多中心、双盲、安慰剂对照试验,纳入220例(分析218例)非吸烟、非电子烟或已戒烟/戒电子烟至少12个月的成人重症COVID-19肺炎有创机械通气≤72小时患者,随机接受每日14 mg尼古丁透皮贴片或安慰剂,直至成功脱机后48小时或最长30天,随后以每周3.5 mg减量3周。主要终点28天死亡率在尼古丁组30/106(28%)与安慰剂组31/112(28%)间无差异(OR 1.03,95%CI 0.57-1.87;p=0.46);28天无呼吸机天数中位数两组均为0(IQR 0-14 vs 0-13;中位数差值0,95%CI -3-7)。可能与尼古丁相关的不良事件罕见(3%)且两组相似。作者结论认为经皮尼古丁未显著降低28天死亡率,此情形无使用尼古丁的指征。
要点
- 重症COVID-19有创机械通气患者中,每日14 mg尼古丁透皮贴片未降低28天死亡率:尼古丁组28% vs 安慰剂组28%(OR 1.03,95%CI 0.57-1.87;p=0.46)。
- 28天无呼吸机天数中位数两组均为0(尼古丁组IQR 0-14 vs 安慰剂组0-13;中位数差值0,95%CI -3-7)。
- 可能与尼古丁相关的不良事件罕见(3%),两组相似。
- 作者结论:经皮尼古丁未显著降低28天死亡率,此情形无使用尼古丁的指征。
- 研究仅纳入非吸烟、非电子烟或已戒烟/戒电子烟至少12个月的成人,且需有创机械通气≤72小时。
适用人群与场景
- 法国18个ICU收治的成人重症COVID-19肺炎患者,正在接受有创机械通气且通气时间≤72小时。
- 仅纳入非吸烟者、非电子烟使用者,或已戒烟/戒电子烟至少12个月者。
- 排除:未明确列出其他排除标准;2例撤回知情同意者被排除分析。
处置流程与药物剂量
- 尼古丁组:经皮贴片每日14 mg,直至成功脱机后48小时或最长30天。
- 随后以每周3.5 mg减量,共3周。
- 随机化按中心、非吸烟或既往吸烟状态、序贯器官功能衰竭评分(<7或≥7)分层。
研究设计与关键结果
- 多中心、双盲、安慰剂对照试验,法国18个ICU,2020年11月6日至2021年4月2日随机220例,排除2例撤回同意后分析218例(男性152例[70%]):尼古丁组106例,安慰剂组112例。
- 主要终点28天死亡率:尼古丁组30/106(28%)vs 安慰剂组31/112(28%);OR 1.03(95%CI 0.57-1.87);p=0.46。
- 28天无呼吸机天数中位数:尼古丁组0(IQR 0-14)vs 安慰剂组0(0-13);中位数差值0(95%CI -3-7)。
- 可能与尼古丁相关的不良事件罕见(3%),两组相似。
证据类型、等级与局限
- 证据类型:多中心、双盲、安慰剂对照随机对照试验。
- 样本量220例随机、218例分析,18个ICU。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为:经皮尼古丁未显著降低28天死亡率,此情形无使用尼古丁的指征。
- 适用人群为重症COVID-19肺炎有创机械通气≤72小时的成人非吸烟/已戒烟者;不适用于未满足上述条件者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Epidemiologic studies have documented lower rates of active smokers compared to former or non-smokers in symptomatic patients affected by coronavirus disease 2019 (COVID-19). We assessed the efficacy and safety of nicotine administered by a transdermal patch in critically ill patients with COVID-19 pneumonia.
METHODS: In this multicentre, double-blind, placebo-controlled trial conducted in 18 intensive care units in France, we randomly assigned adult patients (non-smokers, non-vapers or who had quit smoking/vaping for at least 12 months) with proven COVID-19 pneumonia receiving invasive mechanical ventilation for up to 72 h to receive transdermal patches containing either nicotine at a daily dose of 14 mg or placebo until 48 h following successful weaning from mechanical ventilation or for a maximum of 30 days, followed by 3-week dose tapering by 3.5 mg per week. Randomization was stratified by centre, non- or former smoker status and Sequential Organ Function Assessment score (< or ≥ 7). The primary outcome was day-28 mortality. Main prespecified secondary outcomes included 60-day mortality, time to successful extubation, days alive and free from mechanical ventilation, renal replacement therapy, vasopressor support or organ failure at day 28.
RESULTS: Between November 6th 2020, and April 2nd 2021, 220 patients were randomized from 18 active recruiting centers. After excluding 2 patients who withdrew consent, 218 patients (152 [70%] men) were included in the analysis: 106 patients to the nicotine group and 112 to the placebo group. Day-28 mortality did not differ between the two groups (30 [28%] of 106 patients in the nicotine group vs 31 [28%] of 112 patients in the placebo group; odds ratio 1.03 [95% confidence interval, CI 0.57-1.87]; p = 0.46). The median number of day-28 ventilator-free days was 0 (IQR 0-14) in the nicotine group and 0 (0-13) in the placebo group (with a difference estimate between the medians of 0 [95% CI -3-7]). Adverse events likely related to nicotine were rare (3%) and similar between the two groups.
CONCLUSION: In patients having developed severe COVID-19 pneumonia requiring invasive mechanical ventilation, transdermal nicotine did not significantly reduce day-28 mortality. There is no indication to use nicotine in this situation.
参考来源
- Labro G, Tubach F, Belin L, et al. Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Intensive Care Med. 2022. PMID: 35676335. doi:10.1007/s00134-022-06721-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。